P-71 KRYSTAL-10: A randomized phase 3 study of adagrasib (MRTX849) in combination with cetuximab vs chemotherapy in patients with previously treated advanced colorectal cancer with KRASG12C mutation
Josep Tabernero, Johanna C. Bendell, Ryan B. Corcoran, S. Kopetz, J. Lee, Melissa J. Davis, James G. Christensen, Andrew Chi, Thian Kheoh, Rona Yaeger
Topics & Concepts
KRASCetuximabMedicineColorectal cancerTolerabilityPhases of clinical researchOncologyInternal medicineCancer researchMEK inhibitorChemotherapyPopulationTargeted therapyCancerPharmacologyMAPK/ERK pathwayAdverse effectSignal transductionBiologyEnvironmental healthBiochemistryColorectal Cancer Treatments and StudiesCancer Treatment and PharmacologyLung Cancer Treatments and Mutations